Merck Subpoenaed By DoJ: Vioxx Investigations Under Way
This article was originally published in The Pink Sheet Daily
Executive Summary
Investigation is focusing on "research, marketing and selling activities" for Vioxx, Merck says. The Securities & Exchange Commission has also opened an "informal inquiry" into the product withdrawal.
You may also be interested in...
SEC Initiates Formal Investigation Into Vioxx Withdrawal
Escalation of SEC's "informal inquiry" is "not unexpected," Merck says. Company anticipates a federal judicial panel will rule in several weeks on motions to consolidate Vioxx personal injury and shareholder lawsuits for coordinated pretrial proceedings.
SEC Initiates Formal Investigation Into Vioxx Withdrawal
Escalation of SEC's "informal inquiry" is "not unexpected," Merck says. Company anticipates a federal judicial panel will rule in several weeks on motions to consolidate Vioxx personal injury and shareholder lawsuits for coordinated pretrial proceedings.
Sen. Grassley Seeks FDA Documents On Vioxx Labeling Changes
Senate Finance Committee chair questions why FDA did not adopt recommendations by a cardio-renal division medical officer that a cardiovascular warning be added to Vioxx labeling. Grassley calls FDA’s drug safety initiative “welcome, albeit late in coming.”